Semaglutide has also been shown to improve cognitive function in animal models of Alzheimers disease
Understanding these alternatives helps clinicians and patients make informed, personalised treatment decisions aligned with NICE guidance, cardiovascular risk, renal function, and individual preferences
Such improvement was still noticeable and indeed even more pronounced (MD 5.6
Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM
If you check more than one of these boxes, its even more important to be proactive about managing your symptoms
Andrea Corona Altimmunes GLP-1 drug shows positive results for alcohol use disorder On Tuesday, Altimmune announced topline data from their Phase 2 RECLAIM trial showing that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced the number of heavy drinking days compared to placebo in patients with moderate to severe alcohol use disorder